Global Perspectives: Current and Future Management of Breast Cancer

Practice changes and a look to the future from ESMO 2022 and beyond in triple-negative breast cancer, HR+, HER2– early and metastatic breast cancer.

September 19 and 21, 2022
Nadia Harbeck


Nadia Harbeck, MD, PhD

Ludwig-Maximilians-University of Munich – Breast Center, Germany


Joyce A. O’Shaughnessy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Faculty Members

Mark Pegram, MD
Stanford Womens Cancer Center, Palo Alto, CA, USA

Hope Rugo, MD, FASCO
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA

William Gradishar, MD
Northwestern Medical Group, chicago, IL, USA

Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Guy Jerusalem, MD, PhD
University of Liège, Belgium

Javier Cortes, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain

Valentina Guarneri, MD, PhD
University of Padua, Padova, Italy

Sample Report

Start discovering the insights

View Report


  • Current and Emerging Biomarkers and Testing Methodologies in BC
  • Current and New Treatments in HER2+ Early BC
  • Advances in HER2+ Metastatic Breast Cancer (mBC)
  • Current and Emerging Approaches in HR+, HER2– Early BC
  • Therapeutic Horizons in HR+, HER2– mBC
  • Maximizing Potential Targeting of HER2 in HER2-Low mBC
  • Advances in Early and Metastatic Triple-Negative Breast Cancer (TNBC)

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.